Systematic review and Meta-analysis of Lianhua Qingwen preparations combined with Oseltamivir in treatment of influenza.
10.19540/j.cnki.cjcmm.20220512.501
- Author:
Yu-Meng YAN
1
;
Xiao-Jing YANG
2
;
Chun-Xia ZHAO
3
;
Ze-Yu LI
1
;
Guo-Zhen ZHAO
1
;
Yu-Hong GUO
3
;
Bo LI
3
;
Qing-Quan LIU
3
Author Information
1. Beijing Hospital of Traditional Chinese Medicine, Capital Medical University Beijing 100010, China Beijing University of Chinese Medicine Beijing 100029, China Beijing Institute of Traditional Chinese Medicine Beijing 100010, China.
2. Department of Traditional Chinese Medicine, Eighth Medical Center, PLA General Hospital Beijing 100091, China.
3. Beijing Hospital of Traditional Chinese Medicine, Capital Medical University Beijing 100010, China Beijing Institute of Traditional Chinese Medicine Beijing 100010, China.
- Publication Type:Systematic Review
- Keywords:
Chinese medicine;
Lianhua Qingwen preparations;
Meta-analysis;
influenza
- MeSH:
Cough/drug therapy*;
Drugs, Chinese Herbal/adverse effects*;
Humans;
Influenza, Human/drug therapy*;
Myalgia/drug therapy*;
Nucleic Acids/therapeutic use*;
Oseltamivir/adverse effects*;
Pharyngitis/drug therapy*;
Rhinorrhea
- From:
China Journal of Chinese Materia Medica
2022;47(15):4238-4247
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to explore the efficacy and safety of Lianhua Qingwen preparations combined with Oseltamivir in the treatment of influenza patients. PubMed, Cochrane Library, EMbase, SinoMed, CNKI, Wanfang, and VIP were searched for the randomized controlled trials(RCTs) involving the comparison between the influenza patients treated with Lianhua Qingwen preparations combined with Oseltamivir and those treated with Oseltamivir alone. Fever clearance time was taken as the primary outcome indicator. Clinical effective rate(markedly effective and effective), time to muscle pain relief, time to sore throat relief, time to cough relief, time to nasal congestion and runny nose relief, time to negative result of viral nucleic acid test, and adverse reactions were taken as the secondary outcome indicators. The data were extracted based on the outcome indicators and then combined. The Cochrane collaboration's tool for assessing risk of bias was used to evaluate the quality of a single RCT, and the grading of recommendations assessment, development and evaluations(GRADE) system to assess the quality of a single outcome indicator. RevMan 5.3 was employed to analyze data and test heterogeneity. Finally, 16 RCTs involving 1 629 patients were included for analysis. The Meta-analysis showed that Lianhua Qingwen preparations combined with Oseltamivir was superior to Oseltamivir alone in the treatment of influenza in terms of clinical effective rate(RR=1.16, 95%CI [1.12, 1.20], P<0.000 01), fever clearance time(SMD=-2.02, 95%CI [-2.62,-1.41], P<0.000 01), time to muscle pain relief(SMD=-2.50, 95%CI [-3.84,-1.16], P=0.000 2), time to sore throat relief(SMD=-1.40, 95%CI [-1.93,-0.85], P<0.000 01), time to cough relief(SMD=-1.81, 95%CI [-2.44,-1.19], P<0.000 01), time to nasal congestion and runny nose(SMD=-2.31, 95%CI [-3.61,-1.01], P=0.000 5), and time to negative result of viral nucleic acid test(SMD=-0.68, 95%CI [-1.19,-0.16], P=0.01). However, due to the low quality of the trials, the above conclusions need to be proved by more high-quality clinical studies. In addition, we still need to attach importance to the adverse reactions of the integrated application of Chinese and western medicines.
